Company: IMNN
Filing Date: 2025-05-19
Form Type: S-1/A
Source: 0001641172-25-011388
Chunk: 39

Company: Imunon, Inc.
Filing Date: 2025-05-19
Form: S-1/A
Chunk 39
---
 (200% of the closing price of our Common Stock on Nasdaq on May 16, 2025). The common warrants will be exercisable beginning on the Initial Exercise Date (i.e., the date on which we file a Current Report on Form 8-K with the SEC giving public notice of Stockholder Approval) and will expire two and one-half (2.5) years after the Initial Exercise Date.The exercise price of the common warrants and the number of shares underlying the common warrants are subject to adjustment, including in the following instances:

| ● | Recapitalization                                                                             
 and Other Events: The exercise prices of the common warrants and number of shares underlying 
 the common warrants are subject to adjustment for stock splits, dividends, combinations,     
 recapitalization and similar events.                                                         |

| ● | Adjustment                                                                                              
 at the “Adjustment Date”: On the Adjustment Date (as defined below), the                                
 exercise price of the common warrants will be reduced (but in no event increased) to the                
 greater of (i) the Floor Price (as defined below) and (ii) the lowest daily dollar volume-weighted      
 average price during the period beginning two full trading days prior to the Adjustment Date            
 and ending on the 10th trading day after the Adjustment Date. Upon any such resulting adjustment        
 of the exercise price of the common warrants, the number of shares of Common Stock issuable             
 under the common warrants will be increased such that the aggregate exercise price of a common          
 warrant (adjusted for any exercises by a holder prior to this adjustment) will remain unchanged         
 following such adjustment. No adjustment in connection with an Adjustment Date or otherwise             
 may result in an adjustment of the exercise price to a price less than the Floor Price. Notwithstanding 
 the foregoing, the number of shares potentially issuable upon exercise of the common warrants           
 is limited by the number of available shares of authorized Common Stock; accordingly, the               
 aggregate number of shares of Common Stock potentially issuable in this offering is limited             
 to a total of 90,000,000 shares of Common Stock, with the number of shares of Common Stock              
 potentially issuable upon exercise of the common warrants determined by subtracting the aggregate       
 number of shares of Common Stock or pre-funded warrants issued in this offering from 90,000,000         
 shares. Each purchaser will receive a pro rata portion of such amount. As a result, the                 
 aggregate number of shares of Common Stock underlying all of the common warrants may increase           
 from 16,666,667 up to